2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Newborn Screening, Omics Technologies, Pathology, Serologic Tests, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Surgical, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Hemoglobinopathies, Sickle Cell Disease, Immunology, GVHD, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, APL, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

6091 Cell population data as potential novel biomarkers of inflammatory toxicities following CD19 CAR-T cell therapy

Bruno Gabriel Nardini Fogo, MS, Newton de Freitas Centurião, Newton Centurião2, Alexandre Eiji Eiji Kayano, MD3, Liliana Mitie Suganuma, MD4, Heitor Duarte de Andrade, MD5, Felipe Medauar Reis De Andrade Moreira, MD6, Gabriela de Toledo Passos Candelaria, MD7, Julia Teixeira Cottas Azevedo, PhD8, Andreza Oliveira dos Santos, MS9, Andrea Rocco Villarinho, N/A10, Lucila Nassif Kerbauy, MD, PhD11, João Carlos de Campos Guerra, MD12
1 Einstein Hospital Israelita, São Paulo, São Paulo, Brazil
2 Einstein Hospital Israelita, São Paulo, São Paulo, Brazil
3 Einstein Hospital Israelita, São Paulo, São Paulo, Brazil, Hospital das Clínicas, São Paulo, São Paulo, Brazil
4 Einstein Hospital Israelita, São Paulo, São Paulo, Brazil, Hospital das Clínicas, São Paulo, São Paulo, Brazil
5 Einstein Hospital Israelita, São Paulo, São Paulo, Brazil
6 Einstein Hospital Israelita, São Paulo, São Paulo, Brazil
7 Einstein Hospital Israelita, São Paulo, São Paulo, Brazil
8 Einstein Hospital Israelita, São Paulo, São Paulo, Brazil
9 Einstein Hospital Israelita, São Paulo, São Paulo, Brazil
10 Einstein Hospital Israelita, São Paulo, São Paulo, Brazil
11 Einstein Hospital Israelita, São Paulo, São Paulo, Brazil
12 Einstein Hospital Israelita, São Paulo, São Paulo, Brazil

Introduction: CAR-T cell therapy is an established treatment for relapsed or refractory hematologic malignancies, including B-cell acute lymphoblastic leukemia (B-ALL), lymphomas, and multiple myeloma. However, biomarkers associated with CAR-T cell expansion and inflammatory toxicities remain incompletely characterized. Early lymphocytosis, particularly within the first 14 days after infusion, has been recognized as a surrogate marker of CAR-T cell expansion and has been associated with inflammatory complications such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS). Cell Population Data (CPD), generated by Sysmex XN hematology analyzers, provide detailed morphological and functional information on leukocyte populations beyond conventional complete blood count (CBC) parameters. We aimed to evaluate CPD parameters as potential biomarkers of CAR-T-related inflammatory adverse events and to investigate their relationship with CAR-T cell expansion.

Methods: We conducted an interim analysis of patients enrolled in a phase I clinical trial evaluating an academic point-of-care-manufactured CD19-directed CAR-T cell product at our institution between 2023 and 2026. CPD parameters were extracted from all CBC analyses performed from infusion through day +30 using a Sysmex XN-1000® analyzer. CAR-T cell expansion and persistence were assessed by flow cytometry on days +2, +7, +10, +14, +21, and +30 according to protocol specifications. The primary outcomes were CRS, ICANS, and IEC-HS. Explanatory variables included CBC parameters and CPD metrics (NE-SSC, NE-SFL, NE-FSC, NE-WX, NE-WY, NE-WZ, LY-X, LY-Y, LY-Z, LY-WX, LY-WY, LY-WZ, MO-X, MO-Y, MO-Z, MO-WX, MO-WY, MO-WZ, HFLC, and HFLC%). Longitudinal changes in hematologic and CPD parameters were analyzed using generalized estimating equations (GEE) with a Gaussian distribution, identity link function, and an autoregressive correlation structure [AR(1)] to account for repeated measurements within patients. Correlations between CPD parameters and CAR-T cell counts measured by flow cytometry were evaluated using Spearman's rank correlation.

Results: Among 17 treated patients, 13 had CPD data available for analysis. Diagnoses included chronic lymphocytic leukemia (n=1), B-cell acute lymphoblastic leukemia (n=5), follicular lymphoma (n=3), and diffuse large B-cell lymphoma (n=4). CRS occurred in 10 patients, predominantly grade 1, with only one grade 2 event. ICANS was observed in two patients (grades 1 and 4), and two patients developed grade 2 IEC-HS. Despite the limited number of events, several CPD parameters showed significant longitudinal associations with inflammatory toxicities. Lymphocyte-derived CPD parameters were associated with CRS (LY-WX, median 403 vs. 221, p=0.030), ICANS (LY-X, median 82 vs. 87 Ch, p=0.030; LY-Y, median 68 vs. 85 Ch, p=0.028; HFLC%, median 0.6% vs. 2.9%, p=0.017), and IEC-HS (HFLC%, median 0.7% vs. 2.0%, p=0.030). Monocyte-derived CPD parameters were also associated with CRS (MO-Y, median 111 vs. 114, p=0.016). Notably, the temporal kinetics of lymphocyte- and monocyte-derived CPD parameters differed between patients who developed CRS and those who did not. Patients who developed CRS exhibited lower CPD values immediately after infusion, followed by a marked increase between days +6 and +10. No significant correlations were observed between CPD parameters and CAR-T cell counts measured by flow cytometry, likely owing to the limited sample size.

Conclusion: CPD parameters have demonstrated clinical utility as biomarkers in inflammatory conditions such as sepsis and may represent an inexpensive and widely available approach for monitoring immune activation following CAR-T therapy. Although limited by the small cohort size, our preliminary findings suggest that longitudinal changes in lymphocyte- and monocyte-derived CPD parameters may be associated with CAR-T-related inflammatory toxicities and may reflect CAR-T cell expansion kinetics. CPD may represent a practical tool for routine monitoring of CAR-T recipients, particularly outside clinical trials where detailed assessments of CAR-T cell expansion and persistence are not readily available. Larger prospective studies are warranted to validate these findings and establish the clinical utility of CPD monitoring in patients receiving CAR-T therapy.

Alexandre Eiji Eiji Kayano, MD: No relevant conflicts of interest to declare.